Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 14/20 | 0.44 |
| ▸ | ATRIP | Q8WXE1 | 12/20 | 0.44 |
| ▸ | PDCD1 | Q15116 | 8/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 8/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 7/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25246480 | 0.85 | ATR (0.56) | ATRATRIPPDCD1CD274CHEK1 | |
| SCHEMBL30443862 | 0.85 | ATR (0.56) | ATRATRIPPDCD1CD274CHEK1 | |
| SCHEMBL25287943 | 0.85 | ATR (0.56) | ATRATRIPPDCD1CD274CHEK1 | |
| SCHEMBL25791074 | 0.84 | PDE4D (0.39) | ATRATRIPPDCD1CD274CHEK1 | |
| SCHEMBL25080342 | 0.83 | ATR (0.50) | ATRATRIPCHEK1PIK3CAMTOR | |
| SCHEMBL25791095 | 0.81 | ATR (0.42) | ATRATRIPPDCD1CD274CHEK1 | |
| SCHEMBL25080597 | 0.81 | ATR (0.54) | ATRATRIPPDCD1CD274CHEK1 | |
| SCHEMBL25790981 | 0.81 | PDE4D (0.43) | ATRATRIPPDCD1CD274CHEK1 | |
| SCHEMBL25790199 | 0.80 | ATR (0.54) | ATRATRIPPDCD1CD274CHEK1 | |
| SCHEMBL25790244 | 0.80 | ATR (0.54) | ATRATRIPPDCD1CD274CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023116594-A1 | SUBSTITUTED FUSED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海安诺达生物科技有限公司 | 2023-06-29 | — | — | WO | disclosed |